Improvement of hematopoietic stem cell transplantation in the targeted therapy era
Hematopoietic stem cell transplantation (HSCT) is one of best ways to treat hematological malignancies. And, allogeneic HSCT has been developing rapidly in our country within recent decades, and accomplished many transplantation schemes and technological systems with Chinese characteristics. Especi...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | ZH |
| Publié: |
Editorial Office of Journal of Third Military Medical University
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/b476ded08c7b4a99b6cbe6ad6f890186 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| Résumé: | Hematopoietic stem cell transplantation (HSCT) is one of best ways to treat hematological malignancies. And, allogeneic HSCT has been developing rapidly in our country within recent decades, and accomplished many transplantation schemes and technological systems with Chinese characteristics. Especially, the mature application of haplo-identical HSCT promotes the transplantation into an era of "everyone has a donor". Nowadays, constantly emerged epigenetic regulators, pathway modulators of leukemia genesis and immune cell therapies have provided more options for physician and patients so far in HSCT. In this article, we summarize the application of new drugs in the whole process of allogeneic HSCT (before, during and after transplantation) and related new technologies and new schemes. We consider that the closer combination of new drugs such as targeted drugs and HSCT is an effective measure to further improve the efficacy and safety of allogeneic HSCT. We should organically integrate the existing technologies and new drugs into the best scheme in order to further enhance the efficacy and improve the quality of life of patients. This is a problem that must be focused on in this field in the future. |
|---|